Biorasi was one of the first CROs in the US to manage biosimilar trials. Trust in our experience to help you navigate this growing field.

Global Biosimilars Experts

Over the next five years, the biosimilar market can expect to see double-digit growth. Biorasi has been managing clinical trials for biosimilars since the very beginning, and are well-entrenched in the biosimilars market. 

There are unique challenges and complexities in managing trials for biologics and other large-molecule therapies that sponsors and CROs with decades of experience in small molecules may find themselves running into when dealing with biosimilar trials. Biorasi has been on the leading edge of biosimilar trials since the very beginning. We have run biosimilar studies in Europe since 2006, and also conducted the first biosimilar study in the US under the Affordable Care Act guidelines, and our experience has continued to grow since then.

Biosimilars are predicted to surpass a $41.7 Billion market by 2024. With so much at stake, it pays to put your trust in an industry leader with a history of specialized experience. Trust Biorasi to manage your biosimilar clinical trial from inception to approval.

"One of the rarest events, where we had to communicate [to Biorasi] to stop the screening rather than boost it."

VP of Global Clinical Development, Top Specialty Pharma

Latest News and Blogs

Pioneers Tackling Interchangeability in Biosimilars

With a global market of USD 3.3 billion during 2016 and a forecast surpassing USD 10.5 billion by 2023, Biosimilars have received more than their fair share of hype in the pharma world due to the undeniable value they bring to the healthcare system in terms of...

The Decision on Timing in the BPCI Act

This week, the path to market for biosimilar developers cleared up just a bit. The Supreme Court made a final decision in the three-year lawsuit between Amgen and Sandoz that sets a precedent regarding the interpretation of some widely-contested language in the BPCI...

Contact Biorasi

4 + 10 =